Notable life science industry activity for this coverage week: FDA approvals, clinical trial milestones, funding rounds, grants, and deals. Pulled from public industry data, not personalized to any one company or account.
This week had the feel of a portfolio shuffle. Companies are moving money around, trading assets, and reshaping what they own. For the firms that help move drugs through development and into clinics, that tends to mean a few things worth noticing.
DBV Technologies filed paperwork to sell up to $150 million in securities over time at market prices, a flexible way for a public company to raise cash as it needs it. That's the kind of move you see when a company is in the middle of running programs and wants to keep the lights on without forcing all the capital out at once. Meanwhile, Mission Therapeutics out-licensed an acute kidney injury asset to Dimerix for up to $292 million, sharpening its own focus on central nervous system programs. Both point to companies being deliberate about where they spend and what they keep.
Jasper Therapeutics is merging with Kira Pharmaceuticals to combine their portfolios of therapies made from living cells that target immune disorders. Cellution Biologics acquired SimpliDerm, a processed human tissue product used in breast reconstruction, which marks Cellution's entry into the U.S. breast reconstruction market. And Angelini Pharma completed its acquisition of Catalyst Pharmaceuticals. These are the kinds of deals that tend to pull in the contract manufacturers and regulatory specialists who help integrate pipelines and navigate approvals across new territories. The European Commission also approved JASCAYD, an oral treatment for two types of progressive lung fibrosis, opening market access in the EU. We only see what we happen to pick up, so treat this as a few signals, not the whole board.